Novogen candidate kills brain cancer stem cells


Wednesday, 04 March, 2015


Novogen candidate kills brain cancer stem cells

Drug development company Novogen (ASX:NRT) has announced the results of a study in which one of its lead candidate products, TRXE-009, successfully killed a library of patient-derived brain cancer cells.

In a study conducted by The Feinstein Institute for Medical Research, cell cultures were taken from subjects with glioblastoma multiform (GBM) and cultured under conditions that promote cancer stem cell growth. These stem-like cancer cells are believed to be responsible for chemotherapy resistance and tumour recurrence.

All cancer cells represented in the library, which were derived from both adult and paediatric patients, responded to TRXE-009 at clinically relevant doses. This suggests a strong therapeutical potential, as killing the highly resistant cancer stem cells is considered a fundamental requirement to successfully treating GBM.

Other preclinical studies have found that TRXE-009 is highly cytotoxic of chemo-resistant paediatric brain cancers as well as neutral and neural crest-derived tumours. The drug has also demonstrated success against melanoma cells, indicating a possible link between brain cancer and melanoma. These studies suggest the candidate preferentially targets tumours with a common embryonic origin in neural/neural crest cells.

Novogen next hopes to confirm TRXE-009’s ability to cross the blood-brain barrier, a key filtering mechanism that effectively blocks the majority of chemotherapy drugs from reaching brain tissue. The company is also collaborating with Feinstein to investigate alternative means of delivering the drug to the brain, including direct injection into the brain cancer and the use of lipid brain-targeting particles injected intravenously.

Novogen (ASX:NRT) shares were trading 73.07% higher at $0.225 as of around 11.30 am on Wednesday.

Image credit: ©freeimages.com/profile/artM

Related Articles

Certain hormone drugs linked to increased brain tumour risk

Prolonged use of certain progestogen hormone drugs has been associated with an increased risk of...

A new pathway for reversible male birth control

Most experimental male birth control drugs use a hammer approach to block sperm production, but...

CRISPR-Cas gene editing eliminates HIV in lab

Scientists deployed CRISPR-Cas molecular scissors and two gRNAs against 'conserved' HIV...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd